Nebenwirkungen · Adcetris
ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 18
HOS-126063 · Präparat HOS-096209
In the clinical trial HD21 (BrECADD) of ADCETRIS as combination therapy, neutropenia led to treatment delays in 0.5% of patients. Grade 3 neutropenia was reported in 0.5% and Grade 4 neutropenia was reported in 9% of patients. A dose reduction was required in 1.1% of patients and there was no treatment discontinuation due to serious neutropenia. All patients received primary prophylaxis with G-CSF (see section 4.2). The frequency of febrile neutropenia was 26.5% in patients who received BrECADD.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage 235d5600ea5a018f558cc181293cbb425c0417ceea955904bec2cb8c5beb718c · Zeichen 11836–12336 im Abschnitt